北京大学学报(医学版) ›› 2016, Vol. 48 ›› Issue (4): 720-724. doi: 10.3969/j.issn.1671-167X.2016.04.030

• 疑难/罕见病例分析 • 上一篇    下一篇

前列腺基底细胞癌3例

刘茁1,马潞林1△,张树栋1,陆敏2,田雨1,何群3,金杰3   

  1. (1. 北京大学第三医院泌尿外科, 北京100191; 2. 北京大学第三医院病理科, 北京100191; 3. 北京大学第一医院泌尿外科, 北京100034)
  • 出版日期:2016-08-18 发布日期:2016-08-18
  • 通讯作者: 马潞林 E-mail:malulin@medmail.com.cn

Basal cell carcinoma of prostate: a report of three cases

LIU Zhuo1, MA Lu-lin1△, ZHANG Shu-dong1, LU Min2, TIAN Yu1, HE Qun3, JIN Jie3   

  1. (1.Department of Urology, Peking University Third Hospital, Beijing 100191,China; 2. Department of Pathology, Peking University Third Hospital, Beijing 100191,China; 3. Department of Urology, Peking University First Hospital, Beijing 100034, China)
  • Online:2016-08-18 Published:2016-08-18
  • Contact: MA Lu-lin E-mail:malulin@medmail.com.cn

摘要:

探讨前列腺基底细胞癌(basal cell carcinoma,BCC)临床病理特点并提高诊疗认识。通过报道3例BCC患者的临床病理特点及诊疗经过,结合文献复习,提高对BCC诊疗特点的认识。3例BCC患者年龄为57~83岁,其中1例因血尿就诊,2例因排尿困难就诊。3例患者均合并前列腺增生,其中2例患者前列腺特异性抗原(prostate specific antigen,PSA)增高,1例PSA正常。病例1前列腺癌侵及膀胱、直肠前筋膜,伴淋巴结转移、骨转移、双肺多发转移,2014年11月2日行膀胱全切+双侧输尿管皮肤造口术+双侧闭孔及髂内淋巴结清扫术,术后病理诊断BCC,2015年1月8日复查盆腔增强MRI提示盆腔内复发,2015年7月11日复查腹部增强CT提示肝多发转移,胰腺转移,2015年10月因前列腺癌死亡。病例2于2015年3月27日行前列腺穿刺病理诊断为BCC,伴肺转移及骨转移,行化疗及内分泌治疗,后行局部放射治疗,2016年1月11日复查正电子发射断层显像与计算机断层显像(positron emission tomography and computed tomography,PET-CT)示患者肺转移瘤及骨转移瘤直径较前增大,数量增多,随访至2016年1月10日患者带瘤生存。病例3外院行经尿道前列腺电切术(transurethral resection of prostate,TURP),术后病理考虑BCC可能,行PET-CT提示残余前列腺恶性肿瘤,伴双侧盆腔淋巴结转移可能,2016年4月20日复查PET-CT提示盆腔可见巨大不规则混杂密度影,临床考虑肿瘤复发,遂予局部放射治疗,随访至2016年1月10日患者带瘤生存。BCC临床罕见,是一种侵袭能力强、恶性程度较高、易发生转移的肿瘤,需要给予积极的治疗和密切的随访。

关键词: 癌, 基底细胞, 癌, 腺样囊性, 前列腺肿瘤

Abstract:

To explore the clinical pathological characteristics and improve the recognition in the diagnosis and treatment of basal cell carcinoma (BCC) of prostate. Three cases of BCC of prostate were reported and the relevant literature was reviewed to investigate the diagnosis and treatment of this disease. We analyzed three cases of prostatic BCC. Their ages were within a range of 57 to 83 years. One of them complained of hematuria and two complained of dysuria. All of them presented with prostatic hyperplasia. Two of them presented with high prostate specific antigen (PSA) and one with normal PSA. Case 1 had prostate cancer invasion of bladder, rectal fascia, with lymph node metastasis, bone metastasis and lung metastases. The patient received bladder resection+bilateral ureteral cutaneous ureterostomy+lymph node dissection on November 2, 2014 . Postoperative pathological diagnosis showed BCC. Reexamination of pelvic enhanced MRI in January 8, 2015 suggested pelvic recurrence. Abdominal enhanced CT showed multiple liver metastases and pancreatic metastasis on July 11, 2015. Prostate cancer specific death occurred in October 2015. Case 2 was diagnosed as BCC in prostate biopsy on March 27, 2015. Positron emission tomography and computed tomography (PET-CT) showed pulmonary metastasis and bone metastasis. Then the patient received chemotherapy, endocrine therapy and local radiation therapy. Reexamination of PET-CT on January 11, 2016 showed that the lung metastase tumors and bone metastase tumors were larger than before. Up to January 10, 2016, the patient was still alive. Postoperative pathological changes of transurethral resection of prostate (TURP) in case 3 showed BCC might be considered. The PET-CT suggested residual prostate cancer, which might be associated with bilateral pelvic lymph node metastasis. In April 20, 2016, the review of PET-CT showed pelvic huge irregular hybrid density shadow, about 14.5 cm×10.0 cm×12.9 cm in size, and tumor recurrence was considered. Then the patient received local radiation therapy. The patient survived in the followed upon January 10, 2016. BCC of prostate is a rare subtype. Due to the local infiltrative and distant metastatic potentiality, active management is preferred and a life-long follow-up is necessary.

Key words: Carcinoma, basal cell, Carcinoma, adenoid cystic, Prostatic neoplasms

中图分类号: 

  • R737.25
[1] 步召德, 冯梦宇, 季科. 早期胃癌行前哨淋巴结导航手术的实践与思考[J]. 北京大学学报(医学版), 2026, 58(2): 239-243.
[2] 王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报(医学版), 2026, 58(2): 251-256.
[3] 罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报(医学版), 2026, 58(2): 257-265.
[4] 付浩, 申潞艳, 黄冰洋, 马少华. 免疫治疗背景下食管鳞状细胞癌围手术期治疗的临床思考[J]. 北京大学学报(医学版), 2026, 58(2): 266-271.
[5] 殷昊明, 王子杰, 舒帆, 张展奕, 梁会, 张树栋. 肾透明细胞癌FABP6基因长转录本的表达及意义[J]. 北京大学学报(医学版), 2026, 58(2): 393-398.
[6] 李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报(医学版), 2026, 58(2): 399-404.
[7] 郭芷均, 俎明, 马超, 张贺军, 张静, 丁士刚. 同时性多发早期胃癌漏诊病灶的临床病理特征[J]. 北京大学学报(医学版), 2026, 58(2): 410-415.
[8] 潘子晨, 陈凯, 侯钰坤, 杨博涵, 张继新, 马永蔌, 田孝东, 杨尹默. 胰腺腺鳞癌临床病理特征与分子机制研究进展[J]. 北京大学学报(医学版), 2026, 58(2): 431-435.
[9] 张铃福, 陈明, 赵小宇, 王港, 崔龙, 凌晓锋, 王立新, 徐智, 郭丽梅, 侯纯升. 原发灶局限于胆囊壁内胆囊癌大体分型及其与预后和癌前病变的相关性[J]. 北京大学学报(医学版), 2026, 58(1): 184-189.
[10] 刘艳华, 陆敏, 赵旭阳, 张宽根, 武睿, 梅放, 戴志豪, 由江峰, 裴斐. 肿瘤转移抑制基因LASS2去磷酸化对液泡型ATP酶活性及前列腺癌侵袭性的影响[J]. 北京大学学报(医学版), 2025, 57(6): 1113-1123.
[11] 王晓林, 李璐瑶, 张雯, 王鸿雁. 3例子宫体中肾样腺癌的临床病理学分析[J]. 北京大学学报(医学版), 2025, 57(6): 1208-1212.
[12] 侯卫华, 宋书杰, 石中月, 刘露, 金木兰. 食管胃结合部具有显著空泡状核特征的神经内分泌癌1例[J]. 北京大学学报(医学版), 2025, 57(5): 1005-1009.
[13] 谢尚, 王鹿鸣, 张馨元, 冯秋实, 夏洋洋, 戴姿薇, 单小峰, 蔡志刚. 口腔鳞癌类器官库的构建及应用[J]. 北京大学学报(医学版), 2025, 57(5): 847-851.
[14] 李浙民, 季加孚, 李国新, 李子禹, 步召德, 高翔宇, 董迪, 唐磊, 邢晓芳, 贾淑芹, 郭婷, 张连海, 陕飞, 季鑫, 王安强. 胃癌精准诊疗技术的创建与推广[J]. 北京大学学报(医学版), 2025, 57(5): 864-867.
[15] 唐少海, 杨宝明, 李建坤, 赵丽丽, 王仪凡, 王顺祥. HDAC2介导H3K27ac修饰促进肝癌细胞的增殖和迁移[J]. 北京大学学报(医学版), 2025, 57(5): 884-894.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!